MORPHOLOGICAL ANALYSIS AND CLASSIFICATION OF LATENT PROSTATE-CANCER USING A 3-DIMENSIONAL COMPUTER ALGORITHM - ANALYSIS OF TUMOR VOLUME, GRADE, TUMOR DOUBLING TIME AND LIFE EXPECTANCY
D. Hirano et al., MORPHOLOGICAL ANALYSIS AND CLASSIFICATION OF LATENT PROSTATE-CANCER USING A 3-DIMENSIONAL COMPUTER ALGORITHM - ANALYSIS OF TUMOR VOLUME, GRADE, TUMOR DOUBLING TIME AND LIFE EXPECTANCY, The Journal of urology, 159(4), 1998, pp. 1265-1269
Purpose: We estimate the potential clinical significance of prostate c
ancers found at autopsy provided the individual had lived to the proje
cted lifespan based on life expectancy tables. Materials and Methods:
We used 3-dimensional computer models of 59 autopsy prostates that con
tained clinically undetected carcinoma to determine tumor volumes. Usi
ng doubling times of 2, 3, 4 and 6 years, carcinoma volumes at autopsy
were extrapolated through patient projected lifespans. The carcinomas
were then classified as clinically insignificant or significant accor
ding to Mayo Clinic criteria. Results: In 13 patients less than 60 yea
rs old, using doubling times of 2, 3, 4 and 6 years, clinically signif
icant tumors were identified in 13 (100%), 10 (77%), 7 (54%) and 7 (54
%), respectively. In 46 patients 60 years old or greater significant t
umors were identified in 32 (70%), 22 (48%), 21 (46%) and 18 (39%), re
spectively. A statistical difference (p <0.0001) was found between the
mean tumor volume (0.20 +/- 0.10 cc) of 43 organ confined carcinomas
and the mean tumor volume (3.26 +/- 3.58 cc) of 16 extracapsular tumor
s. No capsule perforation was found in tumors with Gleason sums of 4 o
r less. However, capsule perforation was present in 8 of 31 tumors (25
.8%) with Gleason sums of 5 or 6, and 8 of 11 tumors (72.7%) with Glea
son scores of 7 or 8. Conclusions: Prostatic carcinomas that remain cl
inically insignificant throughout life are likely to have doubling tim
es greater than 4 years. The subset of carcinomas that emerge as clini
cally significant are likely to have doubling times less than 3 years.
Therefore, an accurate method to measure doubling time at diagnosis c
ould, provide an objective indicator to guide clinical management.